Becker's Healthcare May 24, 2024
Around four in 10 Health Alliance members taking adalimumab are prescribed biosimilar versions, and the plan is taking the leap to remove brand-name versions of the high-cost drug from its formulary.
Humira, used to treat rheumatoid arthritis and other conditions, can cost upward of $6,000 a month, and is the highest-grossing drug of all time. Biosimilar versions can cost significantly less.
Biosimilar versions of adalimumab were introduced in January of 2023, and approaches to the drug from insurers and pharmaceutical benefit managers have varied. In April, CVS Caremark removed brand-name Humira from its formulary. Optum, another large PBM, covers biosimilars and brand-name Humira on the same tier in its formulary.
Champaign, Ill.-based Health Alliance plan has 250,000...
Today's Sponsors
Today's Sponsor